Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Andrea Martoni

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Antineoplastic Combined Chemotherapy Protocols

Disorders

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Drug Evaluation

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
69
Pannuti, F
22
Piana, Edera
22
Guaraldi, Monica
20
Strocchi, Elena
16
Lelli, Giorgio
15
Zamagni, Claudio
12
Pinto, Carmine
12
Camaggi, Carlo Maurizio
11
Angelelli, B
9
Giaquinta, Stefania
8
Cacciari, N
7
Di Fabio, Francesca
6
Marino, Antonella
6
Mutri, Vita
6
Panetta, A

Sign-in to see all Coauthors

Publications

TOP 3
Pinto C; Di Fabio F; Barone C; Siena S; Falcone A; Cascinu S; Rojas Llimpe F L; Stella G; Schinzari G; Artale S; Mutri V; Giaquinta S; Giannetta L; Bardelli A; Martoni A A
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).
Martoni A A; Melotti B; Sperandi F; Giaquinta S; Piana E; Pavesi L; Da Prada G; Lelli G
Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
Funaioli Chiara; Pinto Carmine; Di Fabio Francesca; Santini Donatella; Ceccarelli Claudio; De Raffaele Emilio; Fanti Stefano; Castellucci Paolo; Longobardi Ciro; Buggi Federico; Martoni Andrea Angelo
18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Andrea Martoni (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Pinto C; Di Fabio F; Barone C; Siena S; Falcone A; Cascinu S; Rojas Llimpe F L; Stella G; Schinzari G; Artale S; Mutri V; Giaquinta S; Giannetta L; Bardelli A; Martoni A A
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).
British journal of cancer 2009;101(8):1261-8.
2008: Martoni A A; Melotti B; Sperandi F; Giaquinta S; Piana E; Pavesi L; Da Prada G; Lelli G
Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
Lung cancer (Amsterdam, Netherlands) 2008;60(3):387-92.
2007: Funaioli Chiara; Pinto Carmine; Di Fabio Francesca; Santini Donatella; Ceccarelli Claudio; De Raffaele Emilio; Fanti Stefano; Castellucci Paolo; Longobardi Ciro; Buggi Federico; Martoni Andrea Angelo
18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy.
Tumori 2007;93(6):611-5.
2007: Joerger Markus; Huitema Alwin D R; Richel Dick J; Dittrich Christian; Pavlidis Nikolas; Briasoulis Evangelos; Vermorken Jan B; Strocchi Elena; Martoni Andrea; Sorio Roberto; Sleeboom Henk P; Izquierdo Miguel A; Jodrell Duncan I; Calvert Hilary; Boddy Alan V; Hollema Harry; Féty Regine; Van der Vijgh Wjf J F; Hempel Georg; Chatelut Etienne; Karlsson Mats; Wilkins Justin; Tranchand Brigitte; Schrijvers Ad H G J; Twelves Christian; Beijnen Jos H; Schellens Jan H M
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6410-8.
2007: Martoni Andrea Angelo; Tanneberger Stephan; Mutri Vita
Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use.
Tumori 2007;93(5):417-22.
2007: Dogliotti Luigi; Cartenì Giacomo; Siena Salvatore; Bertetto Oscar; Martoni Andrea; Bono Aldo; Amadori Dino; Onat Haluk; Marini Luca
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
European urology 2007;52(1):134-41.
2007: Gridelli Cesare; Kaukel Eckhard; Gregorc Vanessa; Migliorino Maria Rita; Müller Thomas R; Manegold Christian; Favaretto Adolfo; Martoni Andrea; Caffo Orazio; Schmittel Alexander; Rossi Antonio; Russo Francesca; Peterson Patrick; Muñoz María; Reck Martin
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(3):221-9.
2007: Pinto C; Di Fabio F; Siena S; Cascinu S; Rojas Llimpe F L; Ceccarelli C; Mutri V; Giannetta L; Giaquinta S; Funaioli C; Berardi R; Longobardi C; Piana E; Martoni A A
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(3):510-7.
2007: Martoni A A; Degli Esposti C; Cricca A; Rocchi G; Giaquinta S
Twice-daily pain monitoring as standard clinical practice for inpatients at a medical oncology unit: a descriptive study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(1):158-62.
2007: Di Fabio Francesca; Pinto Carmine; Rojas Llimpe Fabiola L; Fanti Stefano; Castellucci Paolo; Longobardi Ciro; Mutri Vita; Funaioli Chiara; Sperandi Francesca; Giaquinta Stefania; Martoni Andrea A
The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2007;10(4):221-7.
2007: Joerger Markus; Huitema Alwin D R; Richel Dick J; Dittrich Christian; Pavlidis Nikolas; Briasoulis Evangelos; Vermorken Jan B; Strocchi Elena; Martoni Andrea; Sorio Roberto; Sleeboom Henk P; Izquierdo Miguel A; Jodrell Duncan I; Féty Régine; de Bruijn Ernst; Hempel Georg; Karlsson Mats; Tranchand Brigitte; Schrijvers Ad H G J; Twelves Chris; Beijnen Jos H; Schellens Jan H M;
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Clinical pharmacokinetics 2007;46(12):1051-68.
2006: Martoni Andrea Angelo; Pinto Carmine; Di Fabio Francesca; Lelli Giorgio; Rojas Llimpe Fabiola Lorena; Gentile Anna Lisa; Mutri Vita; Ballardini PierLuigi; Giaquinta Stefania; Piana Edera
Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial).
European journal of cancer (Oxford, England : 1990) 2006;42(18):3161-8.
2006: Martoni Andrea A; Bernardi Alessandra; Quercia Sara
Trastuzumab plus estrogen suppression as salvage treatment in a case of liver failure due to metastatic breast cancer.
Anticancer research 2006;26(5B):3739-44.
2006: Cricca Antonia; Marino Antonella; Valenti Danila; Melotti Barbara; Amaducci Elena; Guardigli Cristina; Lenzi Manuela; Martorana Giuseppe; Buli Pierfrancesco; Martoni Andrea Angelo;
Gemcitabine plus mitoxantrone and prednisone in the palliative treatment of hormone-resistant prostate cancer (HRPC): A phase II study (GOAM 01.01 study).
Anticancer research 2006;26(3B):2301-6.
2006: Funaioli Chiara; Pinto Carmine; Mutri Vita; Di Fabio Francesca; Ceccarelli Claudio; Martoni Andrea Angelo
Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?
Clinical colorectal cancer 2006;6(1):38-45.
2006: Pinto Carmine; Marino Antonella; De Pangher Manzini Vincenzo; Benedetti Giovanni; Galetta Domenico; Mazzanti Paola; Del Conte Guido; dell'Amore Davide; Piana Edera; Giaquinta Stefania; Lopez Massimo; Martoni Andrea
Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
Lung cancer (Amsterdam, Netherlands) 2006;52(2):199-206.
2006: Martoni Andrea Angelo; Di Fabio Francesca; Melotti Barbara; Giaquinta Stefania; Guaraldi Monica
Planned sequence of gemcitabine followed by vinorelbine in the treatment of elderly patients with advanced non-small cell lung cancer.
Anticancer research 2006;26(2B):1501-5.
2005: Martoni A; Marino A; Sperandi F; Giaquinta S; Di Fabio F; Melotti B; Guaraldi M; Palomba G; Preti P; Petralia A; Artioli F; Picece V; Farris A; Mantovani L
Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(1):81-92.
2004: Martoni Andrea; Cucinotta Domenico; Balducci Lodovico
Meeting report: Breast cancer in the older woman.
Tumori 2004;90(4):437-45.
2004: Nanni Cristina; Castellucci Paolo; Farsad Mohsen; Pinto Carmine; Moretti Andrea; Pettinato Cinzia; Marengo Mario; Boschi Stefano; Franchi Roberto; Martoni Andrea; Monetti Nino; Fanti Stefano
Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.
Cancer biotherapy & radiopharmaceuticals 2004;19(2):149-54.
2004: Cresta S; Grasselli G; Mansutti M; Martoni A; Lelli G; Capri G; Buzzi F; Cuna G Robustelli Della; Jirillo A; Terzoli E; Frevola L; Tarenzi E; Sguotti C; Azli N; Murawsky M; Gianni L
A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(3):433-9.
2004: Ballardini Pierluigi; Incasa Elena; Del Noce Antonio; Cavazzini Luigi; Martoni Andrea; Piana Edera
Spontaneous splenic rupture after the start of lung cancer chemotherapy. A case report.
Tumori 2004;90(1):144-6.
2003: Granetto Cristina; Ricci Sergio; Martoni Andrea; Pezzella Giuseppe; Testore Franco; Mattioli Rodolfo; Lampignano Maria; Tacconi Fiorenzo; Porrozzi Stella; Gasparini Giampietro; Mantovani Giovanni;
Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.
Oncology reports 2003;10(5):1289-96.
2003: Lønning Per; Pfister Christian; Martoni Andrea; Zamagni Claudio
Pharmacokinetics of third-generation aromatase inhibitors.
Seminars in oncology 2003;30(4 Suppl 14):23-32.
2003: Martoni Andrea; Cucinotta Domenico
Breast cancer in the older woman.
Critical reviews in oncology/hematology 2003;46(3):207-9.
2003: Capotorto A M; Pavesi L; Pedrazzoli P; Da Prada G A; Zamagni C; Massidda B; Farris A; Martoni A; Lelli G; Robustelli della Cuna G
Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
Journal of chemotherapy (Florence, Italy) 2003;15(2):184-91.
2003: Nanni Christina; Fanti Stefano; Pinto Carmine; Farsad Mohsen; Moretti Andrea; Franchi Roberto; Martoni Andrea; Monetti Nino
Scintigraphic findings in necrotizing myopathy.
Clinical nuclear medicine 2003;28(2):118-20.
2003: Martoni A; Mini E; Pinto C; Gentile A L; Nobili S; Dentico P; Marino A; Scicolone S; Angelelli B; Mazzei T
Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study.
Anticancer research 2003;23(1B):687-91.
2001: Martoni A; Di Fabio F; Guaraldi M; Piana E; Ramini R; Lelli G; Palomba G; Artioli F; Bandieri E; Robustelli Della Cuna G; Preti P
Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer.
American journal of clinical oncology 2001;24(6):614-7.
2001: Martoni A; Mini E; Pinto C; Gentile A; Mazzei T
[Oxaliplatin: combinations with thymidylate synthetase inhibitors: two consecutive phase II studies]
Tumori 2001;87(6):A25-6.
2001: Costa S; Terzano P; Santini D; Ceccarelli C; Martoni A; Angelelli B; Panetta A; Bovicelli A; Cristiani P; Lipponen P; Erzén M; Syrjänen S; Syrjänen K
Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis, and proliferation as determinants of response to therapy and disease outcome.
American journal of clinical pathology 2001;116(5):729-37.
2001: Guaraldi M; Marino A; Pannuti F; Farabegoli G; Martoni A
Phase II study of sequential treatment of advanced non-small-cell lung cancer: three cycles of high-dose epirubicin plus cisplatin followed by weekly vinorelbine.
Clinical lung cancer 2001;3(1):43-6; discussion 47-8.
2001: Pfister C U; Martoni A; Zamagni C; Lelli G; De Braud F; Souppart C; Duval M; Hornberger U
Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients.
Biopharmaceutics & drug disposition 2001;22(5):191-7.
2001: Martoni A; Mini E; Pinto C; Nobili S; Gentile A L; Dentico P; Angelelli B; Scicolone S; Piana E; Mazzei T
Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(4):519-24.
2001: Pinto C; Marino A; Guaraldi M; Melotti B; Piana E; Martoni A; Pannuti F
Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
American journal of clinical oncology 2001;24(2):143-7.
2001: Costa S; Terzano P; Bovicelli A; Martoni A; Angelelli B; Santini D; Ceccarelli C; Lipponen P; Erzén M; Syrjänen S; Syrjänen K
CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma.
Gynecologic oncology 2001;80(1):67-73.
2000: Cacciari N; Zamagni C; Martoni A
The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?
European journal of gynaecological oncology 2000;21(1):84-5.
1999: Panetta A; Angelelli B; Martoni A
Pilot study on induction chemotherapy with cisplatin, epirubicin, etoposide and bleomycin in cervical cancer stage Ib, IIa and IIb.
Anticancer research 1999;19(1B):765-8.
1999: Martoni A; Guaraldi M; Piana E
Anthracyclines in non-small-cell lung cancer: do they have a therapeutic role?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 5():S19-23.
1999: Cacciari N; Zamagni C; Strocchi E; Pannuti F; Martoni A
Advanced ovarian cancer patients with no evidence of disease after platinum-based chemotherapy: retrospective analysis of the role of second-look.
European journal of gynaecological oncology 1999;20(1):56-60.
1998: Martoni A; Guaraldi M; Piana E; Strocchi E; Petralia A; Busutti L; Preti P; Robustelli G; Raimondi M; Ferrara G; Palomba G; Lelli G; Picece V; Recaldin E; Caffo O; Ambrosini G; Sarobba G; Farris A; Pannuti F
Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 1998;22(1):31-8.
1998: Zamagni C; Martoni A; Cacciari N; Gentile A; Pannuti F
The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer: a phase I-II study.
American journal of clinical oncology 1998;21(5):491-7.
1998: Martoni A; Piana E; Strocchi E; Angelelli B; Guaraldi M; Zamagni C; Camaggi C M; Pannuti F
Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis.
Anticancer research 1998;18(4B):2799-803.
1998: Tanneberger S; Pannuti F; Mirri R; Panetta A; Mariano P; Romano D; Giordani S; Martoni A; Farabegoli G
Hospital-at-Home for advanced cancer patients within the framework of the Bologna Eubiosia project: an evaluation.
Tumori 1998;84(3):376-82.
1997: Fanti S; Bellanova B; Chiti A; Romeo A; Petronelli A; Panetta A; Martoni A; Bertoni F; Bombardieri E; Monetti N
Somatostatin receptor scintigraphy in a patient with an epigastric mass and multiple liver metastases.
Clinical nuclear medicine 1997;22(11):802-3.
1997: Bruzzone M; Rubagotti A; Gadducci A; Catsafados E; Foglia G; Brunetti I; Giannessi P G; Carnino F; Iskra L; Rosso R; Martoni A; Pannuti F; De Lisi V; Maltoni R; Ridolfi R; Mammoliti S; Gallo L; Boccardo F; Ragni N; Conte P F
Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest.
Gynecologic oncology 1997;65(3):499-505.
1997: Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
Chemotherapy of advanced ovarian cancer.
Frontiers in bioscience : a journal and virtual library 1997;2():g20-6.
1996: Cacciari N; Martoni A; Rossi A P; Turci P; Lelli G; Martinelli A; Maver P; Corrado F; Mannini D; Reggiani A; Concetti S; Martelli A; Melotti B; Cricca A; Zamagni C; Pannuti F
A new regimen of cisplatin, epirubicin and methotrexate (PEM-3) as primary chemotherapy for locally advanced bladder cancer.
Tumori 1996;82(4):364-8.
1996: Martoni A; Angelelli B; Guaraldi M; Strocchi E; Pannuti F
An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens.
European journal of cancer (Oxford, England : 1990) 1996;32A(1):82-5.
1995: Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
European journal of cancer (Oxford, England : 1990) 1995;31A(10):1615-21.
1995: Martoni A; Bidin L; Zamagni C; Cricca A; Pannuti F
Failure to increase 5-fluorouracil activity with interferon-alpha 2a in the treatment of advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(1):127.
1995: Camaggi C M; Strocchi E; Martoni A; Zamagni C; Cacciari N; Robustelli della Cuna G; Pavesi L; Tedeschi M; Silva A; Pannuti F
Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies.
Cancer chemotherapy and pharmacology 1995;36(4):356-9.
1994: Panetta A; Martoni A; Guaraldi M; Tamberi S; Casadio M; Lelli G; Pannuti F
Combined chemo-immuno-hormonotherapy of advanced renal cell carcinoma.
Journal of chemotherapy (Florence, Italy) 1994;6(5):349-53.
1994: Pedrazzoli P; Zamagni C; Martoni A; Capotorto A M; Da Prada G A; Pavesi L; Preti P; Lelli G; Pannuti F; Robustelli della Cuna G
Dose intensification of chemotherapy in advanced breast cancer: a feasibility phase II study.
Tumori 1994;80(4):273-5.
1993: Robustelli della Cuna G; Pannuti F; Martoni A; Camaggi C M; Strocchi E; Da Prada G A; Tanneberger S
Aminoglutethimide in advanced breast cancer: prospective, randomized comparison of two dose levels. Italian Cooperative Group.
Anticancer research 1993;13(6B):2367-71.
1993: Martoni A; Panetta A; Angelelli B; Melotti B; Pannuti F
A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma.
Journal of chemotherapy (Florence, Italy) 1993;5(1):47-51.
1993: Camaggi C M; Strocchi E; Carisi P; Martoni A; Melotti B; Pannuti F
Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study.
Cancer chemotherapy and pharmacology 1993;32(4):301-9.
1993: Pannuti F; Guaraldi M; Martoni A; Melotti B; Morritti M G
Folinic acid plus 5-FU based chemotherapy in squamous cell carcinoma of the head and neck: Bologna experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4 Suppl 2():45-8.
1992: Martoni A; Guaraldi M; Casadio M; Busutti L; Pannuti F
A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small-cell lung cancer (NSCLC).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(10):864-6.
1992: Zamagni C; Martoni A; Cacciari N; Bellanova B; Vecchi F; Pannuti F
CA-549 serum levels in breast cancer monitoring.
The International journal of biological markers 1992;7(4):217-21.
1992: Tanneberger S; Lelli G; Martoni A; Piana E; Pannuti F
The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index).
Journal of chemotherapy (Florence, Italy) 1992;4(5):326-31.
1992: Martoni A; Cricca A; Guaraldi M; Covizzi M; Farris A; Pannuti F
Weekly regimen of 5-FU vs 5-FU + intermediate dose folinic acid in the treatment of advanced colorectal cancer.
Anticancer research 1992;12(3):607-12.
1992: Martoni A; Cricca A; Guaraldi M; Covizzi M; Farris A; Pannuti F
Randomized clinical trial with a weekly regimen of 5-FU vs 5-FU + intermediate-dose folinic acid in the treatment of advanced colo-rectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(1):87-8.
1992: Camaggi C M; Strocchi E; Carisi P; Martoni A; Tononi A; Guaraldi M; Strolin-Benedetti M; Efthymiopoulos C; Pannuti F
Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study.
Cancer chemotherapy and pharmacology 1992;30(4):307-16.
1991: Guaraldi M; Martoni A; Tononi A; Occhiuzzi L; Caliceti U; Dall'Olio D; Laudadio P; Pannuti F
5-fluorouracil + folinic acid with cisplatinum and bleomycin in the treatment of advanced head and neck squamous cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(5):379-81.
1991: Zamagni C; Martoni A; Ercolino L; Baroni M; Tanneberger S; Pannuti F
5-Fluorouracil, epirubicin and cyclophosphamide (FEC combination) in advanced breast cancer.
Journal of chemotherapy (Florence, Italy) 1991;3(2):126-9.
1991: Strocchi E; Camaggi C M; Martoni A; Cellerino R; Miseria S; Malacarne P; Indelli M; Balli M; Bonciarelli G; Ambroso G
Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses.
Cancer chemotherapy and pharmacology 1991;27(6):451-5.
1991: Periti P; Pannuti F; Della Cuna G R; Mazzei T; Mini E; Martoni A; Preti P; Ercolino L; Pavesi L; Ribecco A
Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma.
Cancer investigation 1991;9(3):249-55.
1991: Martoni A; Guaraldi M; Camera P; Biagi R; Marri S; Beghé F; Pannuti F
Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton.
Oncology 1991;48(2):97-101.
1991: Martoni A; Longhi A; Canova N; Pannuti F
High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients.
Oncology 1991;48(1):1-6.
1991: Martoni A; Melotti B; Guaraldi M; Pannuti F
Activity of high-dose epirubicin in advanced non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(10):1231-4.
1990: Martoni A; Ercolino L; Bellucco A; Canova N; Lelli G; Pannuti F
Cisplatinum plus epirubicin alternated with cyclophosphamide plus 5-fluorouracil in ovarian cancer.
Journal of chemotherapy (Florence, Italy) 1990;2(1):62-6.
1990: Martoni A; Piana E; Guaraldi M; Cilenti G; Farris A; Saccani F; Becchi G; Pannuti F
Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer.
Oncology 1990;47(5):427-32.
1990: Martoni A; Melotti B; Guaraldi M; Pacciarini M A; Riva A; Pannuti F
High-dose epirubicin for untreated patients with advanced tumours: a phase I study.
European journal of cancer (Oxford, England : 1990) 1990;26(11-12):1137-40.
1989: Martoni A; Cricca A; Guaraldi M; Farris A; Pannuti F
A randomized clinical trial with a weekly regimen of 5-fluorouracil with or without folinic acid in advanced gastrointestinal adenocarcinomas: a preliminary report.
Journal of chemotherapy (Florence, Italy) 1989;1(3):197-202.
1989: Martoni A; Bellucco A; Canova N; Pannuti F
Four-year analysis of platinum and anthracycline combination for ovarian cancer.
Oncology 1989;46(2):109-16.
1988: Martoni A; Rani P; Ercolino L; Canova N; Pannuti F
Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1988;7(5):345-9.
1988: Guaraldi M; Martoni A; Rossi A P; Romagnoli D; Occhiuzzi L; Caliceti U; Pannuti F
Treatment of advanced head and neck tumors with PEV-B regimen: a pilot study.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1988;7(5):341-4.
1988: Martoni A; Ercolino L; Bellanova B; Zanichelli L; Canova N; Pannuti F
CA 15.3 and CEA plasma level monitoring in patients with breast cancer.
The International journal of biological markers 1988;3(3):154-8.
1988: Pannuti F; Coppi G; Borella F; Martoni A; Urbano L; Melotti B
Pharmacokinetics of PTT-119 in man.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1988;7(2):113-6.
1988: Pannuti F; Martoni A; Cilenti G; Camaggi C M; Fruet F
Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients.
European journal of cancer & clinical oncology 1988;24(3):423-9.
1987: Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1987;6(6):396-8.
1987: Lelli G; Casadio M; Giordani S; Giuliotti C; Canova N; Martoni A; Pannuti F
4'-Epidoxorubicin plus cisplatin as first-line therapy in the treatment of small cell bronchogenic carcinoma.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1987;6(2):134-6.
1986: Martoni A; Pacciarini M A; Piana E; Pannuti F
A pilot study of oral idarubicin in metastatic melanoma.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1986;5(6):414-5.
1986: Martoni A; Bellucco A; Marabini A; Orlandi C; Platé L; Bianchi D; Pannuti F
CA-125 monitoring during chemotherapy for ovarian cancer.
The International journal of biological markers 1986;1(3):121-8.
1986: Lelli G; Casadio M; Giuliotti C; Giordani S; Martoni A; Strocchi E; Pannuti F
Phase II studies on weekly cisplatinum plus epirubicin or etoposide in the treatment of advanced non-small cell bronchogenic carcinoma.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1986;5(4):228-31.
1986: Pannuti F; Camaggi C M; Strocchi E; Martoni A
MPA at high doses in advanced breast cancer: a statistical evaluation.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1986;5(3):159-63.
1985: Martoni A; Pacciarini M A; Pannuti F
Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer.
European journal of cancer & clinical oncology 1985;21(7):803-6.
1985: Pannuti F; Martoni A; Farabegoli G; Piana E
Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1985;4(2):127-34.
1985: Pannuti F; Martoni A; Lelli G; Camaggi C M; Strocchi E; Fruet F
[New anthracyclines in the treatment of solid tumors in the advanced stage]
Giornale italiano di chemioterapia 1985;32(1):49-56.
1985: Periti P; della Cuna G R; Pannuti F; Mazzei T; Preti P; Martoni A; Mini E
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer.
Investigational new drugs 1985;3(2):167-71.
1985: Martoni A; Pacciarini M A; Pannuti F
The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
Drugs under experimental and clinical research 1985;11(2):127-31.
1985: Camaggi C M; Strocchi E; Martoni A; Angelelli B; Comparsi R; Pannuti F
Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients.
Drugs under experimental and clinical research 1985;11(4):285-94.
1985: Pannuti F; Martoni A; Murari G; De Sanctis R; Fruet F; Strocchi E
Analgesic activity of medroxyprogesterone acetate (MAP) in cancer patients: an antiinflammatory mediated activity?
International journal of tissue reactions 1985;7(6):505-8.
1984: Martoni A; Tomasi L; Farabegoli G; Fruet F; Pannuti F
4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer.
Cancer treatment reports 1984;68(11):1391-3.
1984: Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1984;3(4):216-9.
1984: Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1984;3(4):211-5.
1984: Martoni A; Tomasi L; Farabegoli G; Giovannini M; Monetti N; Ganzina F; Pannuti F
A phase II study of 4'-epi-doxorubicin plus cis-platinum in advanced solid tumors.
European journal of cancer & clinical oncology 1984;20(1):11-7.
1984: Martoni A; Giovannini M; Tomasi L; Camaggi C M; Bellanova B; Monetti N; Rossini G; Tarquinii M; Martini A; Pannuti F
A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors.
Cancer chemotherapy and pharmacology 1984;12(3):179-82.
1983: Pannuti F; Piana E; Palenzona D; Lenaz G R; Rocchetta G; Nanni P; Rubino I; Murari G; Martoni A; Saccani Joti G
The prevention of the cardiotoxic effects of adriamycin by means of strophanthin. Preclinical study (chick embryo test).
Panminerva medica 1983;25(1):1-6.
1982: Pannuti F; Di Marco A R; Martoni A; Fruet F; Strocchi E; Burroni P; Marraro D
[Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages]
Minerva ginecologica 1982;34(11):977-9.
1982: Camaggi C M; Strocchi E; Tamassia V; Martoni A; Giovannini M; Lafelice G; Canova N; Marraro D; Martini A; Pannuti F
Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.
Cancer treatment reports 1982;66(10):1819-24.
1982: Martoni A; Giovannini M; Pollutri E; Burroni P; Saccani-Jotti G; Pannuti F
[Effect of medroxyprogesterone acetate (MAP) in high doses on chlorambucil-induced bone marrow depression. Preliminary results]
Archivio per le scienze mediche 1982;139(4):449-53.
1982: Pannuti F; Martoni A; Busutti L; Gramellini M; Piana E
High-dose medroxyprogesterone acetate in advanced male breast cancer.
Cancer treatment reports 1982;66(9):1763-5.
1982: Pannuti F; Martoni A; Fruet F; Di Marco A R; Piana E; Saccani-Jotti G; Manfredi D; Mattioli G; Barbanti F; Battelli T; Franchini A; Marrano D; Lungarotti F; Bergnach A
Surgical adjuvant hormonal therapy with high dose medroxyprogesterone acetate (MAP) in breast cancer. Results 36 months after mastectomy.
Panminerva medica 1982;24(3):187-94.
1981: Pannuti F; Martoni A; Fruet; Marraro D; Strocchi E
New regimen of combination hormone therapy (ME-TA-MAP) in the treatment of advanced breast cancer. A pilot study.
Panminerva medica 1981;23(3):157-60.
1981: Pannuti F; Rossi A P; Di Marco A R; Fruet F; Lelli G; Strocchi E; Rocchetta G; Piana E; Martoni A
Monochemotherapy (Adriamycin) for metastatic breast cancer in progression after sequential hormone-chemotherapy (MAP and CMF). Pilot study.
Panminerva medica 1981;23(1):25-8.
1980: Martoni A; Pedelini G; Colalongo G; Biagi R; Mambelli M; Jafelice G; Rocchetta G; Piana E; Pannuti F
[Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses]
Minerva medica 1980;71(31):2215-9.
1980: Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco A R
Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
European journal of cancer 1980;Suppl 1():93-8.

Sign-in to see more